Eyenovia Inc Stock Price, News & Analysis

Eyenovia, Inc. (NASDAQ: EYEN) announced that Dr. Sean Ianchulev will present at the Eyecelerator conference on April 21, 2022, in Washington, DC. The presentation will focus on glaucoma therapies and the innovative Optejet® technology. Dr. Ianchulev emphasized its potential to enhance the effectiveness of current glaucoma treatments. The session titled 'Changing the Way We Look at Glaucoma' will take place from 3:30 PM to 4:14 PM EDT, highlighting the company's mission to improve patient outcomes through advanced ophthalmic solutions.

Eyenovia, Inc. (NASDAQ: EYEN) announced positive results from its "SPEED" study, demonstrating the efficacy of a single microdose array print (MAP™) spray via the proprietary OpteJet® dispenser. Presenting at the American Society of Cataract and Refractive Surgery Annual Meeting, the study showed that nearly 75% of patients achieved clinically meaningful pupil dilation within 15 minutes. The MAP technology was noted for its high success rate (98%) in drug administration without any reported adverse events. This advancement may reduce side effects associated with traditional eye drops.

Eyenovia, Inc. (NASDAQ: EYEN) announced key developments, including a successful Type A meeting with the FDA, setting the stage for the resubmission of the MydCombi NDA in Q3 2022. The company enrolled its first patient in the Phase 3 VISION-2 study for MicroLine, targeting presbyopia treatment. Eyenovia secured a $15 million agreement with Armistice Capital to support clinical and manufacturing efforts. Financially, Q4 2021 net income was $3.0 million, a turnaround from a net loss of $4.2 million in Q4 2020, with total 2021 license revenue reaching $10 million.

Eyenovia, Inc. (NASDAQ: EYEN) will announce its financial results for Q4 and the full year ended December 31, 2021, on March 28, 2022, after market close. The company plans to host a conference call at 4:30 PM ET on the same day to discuss these results. Participants can join by calling 877-407-9039 (domestic) or 201-689-8470 (international) using conference code 13727374. A live webcast will be available on the company's investor relations website. This event will also be archived for one year.

Eyenovia, Inc. (NASDAQ: EYEN) announced positive results from a study with Tufts Medical Center evaluating its Optejet microdose technology against standard eye drops using Latanoprost + Benzalkonium Chloride (BAK). The study demonstrated that Optejet significantly reduced ocular surface damage compared to traditional methods. This new approach minimizes the toxic effects associated with preservatives found in standard treatments, which is a major concern for patients using long-term ocular therapies for conditions like glaucoma. The findings support the efficacy of Eyenovia's innovative MAP™ therapeutics.

Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company, has announced a Securities Purchase Agreement with Armistice Capital, raising approximately $15 million through the offering of 3 million shares of common stock and warrants. The offering is priced at $3.08 per share, reflecting the market price as of March 3, 2022. The proceeds will support the MydCombi program, enhance manufacturing capabilities, and cover working capital. The offering is scheduled to close around March 7, 2022, pending customary conditions.

Eyenovia, Inc. (NASDAQ: EYEN) announced a successful Type A meeting with the FDA regarding the resubmission of its NDA for MydCombi, a drug-device combination product for pupil dilation. Following a complete response letter in October 2021, the FDA requested additional device testing but no further clinical studies. Eyenovia plans to resubmit the NDA in Q3 2022. The company is also advancing its MicroLine Phase 3 clinical trial for presbyopia, targeting a nearly $8 billion market in the U.S. Further details will be shared during the upcoming quarterly update.

Eyenovia, Inc. (NASDAQ: EYEN) announced significant changes to its Board of Directors. Dr. Sean Ianchulev has been appointed Chairman, while Kenneth Lee, Jr. assumes the role of Lead Director. New members Rachel Jacobson and Stephen Benjamin join the Board, bringing diverse expertise in business development and public sector leadership, respectively. Dr. Ernest Mario has retired from the Board after nearly eight years. The company is focused on the late-stage development of its microdose array print (MAP™) therapeutics for eye conditions.

Eyenovia, Inc. (NASDAQ: EYEN) reported its Q3 2021 financial results, noting a net loss of $5.6 million, or $(0.21) per share, reflecting a slight increase in losses year-over-year. The company has initiated the VISION-2 Phase 3 trial for its MicroLine presbyopia treatment, with data expected mid-2022. Eyenovia anticipates the cash resources of approximately $30 million will cover ongoing projects, including the MydCombi NDA resubmission in early 2022. Dr. Fred Eshelman will step down from the Board by year-end. The company aims for potential milestones in 2022 and 2023.